DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
A Delaware federal judge ruled that Novartis AG cannot block MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before the patent expires in late 2026. The judge found that MSN Laboratories Ltd.'s generic copies do not infringe on a key patent held by Novartis. This decision allows MSN to sell its generic Entresto upon FDA approval, potentially introducing competition to Novartis's product ahead of the patent expiration. The ruling marks a setback for Novartis, which had sought to prevent the generic launch through legal action.
Novartis could soon face generic competition for Entresto after judge's ruling $NVS https://t.co/Kf09ykLDQY
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent expires late 2026, a judge ruled. More top news in The Afternoon Docket. Subscribe here ➡️ https://t.co/pBFi0AwVRm https://t.co/mXNbNL3Kl6
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent expires late next year, a Delaware federal judge said on Friday. https://t.co/nSE4qQpG61
